Sep 8, 2026 04:05PM
Aug 13, 2026 04:05PM
Aug 12, 2026 04:01PM
Aug 5, 2026 08:30AM
May 19, 2026 04:45PM
May 14, 2026 04:10PM
May 13, 2026 04:01PM Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 6, 2026 04:01PM
Apr 21, 2026 08:30AM
Apr 21, 2026 08:30AM
Mar 31, 2026 04:05PM
Mar 30, 2026 04:05PM
Mar 30, 2026 04:05PM
Mar 25, 2026 04:01PM Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Mar 18, 2026 08:30AM
Feb 23, 2026 09:24AM
Feb 23, 2026 09:24AM
Feb 23, 2026 08:30AM
Feb 23, 2026 08:30AM
Feb 23, 2026 08:00AM
Feb 23, 2026 08:00AM Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Jan 13, 2026 07:45AM
Jan 13, 2026 07:45AM
Jan 12, 2026 05:11PM
Dec 15, 2025 08:03AM
Dec 15, 2025 08:00AM
Dec 10, 2025 08:30AM
Dec 10, 2025 08:30AM Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Nov 14, 2025 08:30AM
Nov 12, 2025 04:01PM
Nov 5, 2025 08:30AM
Oct 24, 2025 08:30AM
Oct 24, 2025 08:30AM
Oct 21, 2025 08:30AM
Oct 21, 2025 08:30AM Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
Oct 8, 2025 08:30AM
Oct 2, 2025 06:47AM
Oct 1, 2025 08:00AM
Sep 3, 2025 08:30AM
Aug 18, 2025 08:30AM
Aug 14, 2025 04:05PM
Aug 12, 2025 04:01PM Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Aug 7, 2025 08:30AM
Aug 7, 2025 08:30AM
Aug 5, 2025 04:01PM
Jul 14, 2025 08:31AM
Jul 14, 2025 08:30AM
Jul 7, 2025 08:32AM
Jul 7, 2025 08:30AM Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
Jun 24, 2025 08:31AM

334,289 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All